Decker T, Soling U, Hahn A, Maintz C, et al. Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positiv BMC Cancer 2020;20:286.
PMID: 32252684